(Q53480219)

English

Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis.

scientific article published on 30 May 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26037898

Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis. (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26037898

1 reference

based on heuristic

inferred from title

Angeles Alvarez Secord

8

object named as

Angeles Alvarez Secord

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26037898

author name string

Rebecca Previs

1

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26037898

Charles A Leath

2

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26037898

Robert L Coleman

3

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26037898

Thomas J Herzog

4

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26037898

Thomas C Krivak

5

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26037898

Stacey L Brower

6

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26037898

Chunqiao Tian

7

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26037898

language of work or name

0 references

publication date

30 May 2015

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26037898

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26037898

138

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26037898

2

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26037898

267-271

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26037898

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

Integrated genomic analyses of ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

Epidemiology of low-grade serous ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

Low-grade serous carcinomas of the ovary contain very few point mutations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

Novel insights on the malignant transformation of endometriosis into ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

ARID1A mutations in endometriosis-associated ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.05.038

7 January 2021

Identifiers

10.1016/J.YGYNO.2015.05.038

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26037898

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26037898

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53480219&oldid=1370858407"